Use of erlotinib and thalidomide in advanced NSCLC patients with acquired resistance to erlotinib: A pilot study

In this study, we firstly confirmed that thalidomide can reversion of erlotinib-acquired resistance with a 7 weeks median progression-free survival (PFS); besides, this combination therapy shows acceptable drug tolerance; the most common drug related adverse events were astriction, numbness and sleeve-like feeling in the limbs, no thrombosis occurred in any patient. Those evidences indicate that thalidomide may be a useful candidate for reversion of erlotinib-acquired resistance.
Source: Pathology Research and Practice - Category: Pathology Source Type: research